Therapeutic Drug Monitoring (TDM) of biologics entails measuring drug and anti-drug antibody concentrations, with subsequent possible dose adjustment to ensure optimised dosing for the patient.
With their high-performance and short turnaround time, i-Tracker CLIA kits, in combination with the i-Track random-access analyser, enable the clinician to make therapeutic decisions promptly.
In giving access to rapid treatment adjustments, i-Tracker assays contribute to improve overall clinical outcomes for the patients while minimising the cost of treatment.
- Innovative CLIA technology
- Short turnaround time
- Validated on princeps and biosimilars
- Calibrated against WHO international standards
Interpret dosing information
- Drug levels required to improve clinical outcomes may vary between patients and depend on the desired therapeutic endpoint.
- In patients with undetectable drug levels, anti-drug antibody (ADAb) quantification helps to identify how to improve patient response.
- In patients considered to be good responders with higher drug trough levels, dose escalation may be possible without affecting clinical outcomes.
- In patients with high anti-drug antibody levels, a switch in class may be necessary.
- In patients with low anti-drug antibody levels, the addition of an immunosuppressive drug may improve clinical outcomes.
Example of therapeutic decision algorithm in patients with loss of response:
| Negative Anti-drug Antibodies | Positive Anti-drug Antibodies | |
| Therapeutic level of Drug | Switch out of therapeutic class |
Retest |
| Subtherapeutic level of Drug | Treatment optimisation | Switch in- [therapeutic] class |
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
